{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:51:19Z","timestamp":1768697479772,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clinthera.2025.06.008","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:17:47Z","timestamp":1751545067000},"page":"696-705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Simnotrelvir-Ritonavir Compared With Nirmatrelvir-Ritonavir in the Treatment of COVID-19: Real-World Evidence From a Retrospective Cohort Study During the Prevalence of the Omicron EG.5 Variant"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8806-847X","authenticated-orcid":false,"given":"Yi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3730-402X","authenticated-orcid":false,"given":"Yuezhen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1797-2215","authenticated-orcid":false,"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunguo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xintong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7996-5002","authenticated-orcid":false,"given":"Zhuoling","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.06.008_bib0001","unstructured":"World Health Organization. EG.5 initial risk evaluation. 2023. Accessed May 24, 2024. Available at: w.w.w.who.int\/docs\/default-source\/coronaviruse\/09082023eg.5_ire_final.pdf."},{"key":"10.1016\/j.clinthera.2025.06.008_bib0002","article-title":"Editorial: a rapid global increase in COVID-19 is due to the emergence of the EG.5 (Eris) subvariant of Omicron SARS-CoV-2","volume":"29","author":"Parums","year":"2023","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial","volume":"7","author":"Yotsuyanagi","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0004","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.2147\/IDR.S445826","article-title":"Nirmatrelvir-ritonavir reduced mortality in hospitalized patients with COVID-19 during the Omicron outbreak: real-world evidence from Beijing","volume":"17","author":"Zhang","year":"2024","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28947","article-title":"Oral azvudine for mild-to-moderate COVID-19 in high risk, nonhospitalized adults: results of a real-world study","volume":"95","author":"Yang","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102359","article-title":"Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial","volume":"67","author":"Zhan","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0007","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s40265-023-01926-0","article-title":"Remdesivir: a review in COVID-19","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0008","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1007\/s11684-023-1037-3","article-title":"Small-molecule anti-COVID-19 drugs and a focus on China\u2019s homegrown mindeudesivir (VV116)","volume":"17","author":"Cao","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0009","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0036","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acsptsci.3c00134","article-title":"Deuremidevir and Simnotrelvir-Ritonavir for the Treatment of COVID-19","volume":"6","author":"Zhu","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106598","article-title":"A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects","volume":"191","author":"Yang","year":"2023","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0012","article-title":"Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial","volume":"38","author":"Wang","year":"2023","journal-title":"Lancet Reg Health\u2014West Pac"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0013","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa2301425","article-title":"Oral simnotrelvir for adult patients with mild-to-moderate Covid-19","volume":"390","author":"Cao","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107096","article-title":"Small-molecule antiviral treatments for COVID-19: a systematic review and network meta-analysis","volume":"63","author":"Zheng","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.70174","article-title":"Effectiveness and safety of simnotrelvir\/ritonavir and nirmatrelvir\/ritonavir in the treatment of moderate to severe COVID-19","volume":"13","author":"Chen","year":"2025","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0016","unstructured":"National Health Commission of the People\u2019s Republic of China. Diagnosis and treatment protocol for novel coronavirus infection (Trial Version 10). 2023. Accessed May 19, 2024. Available at: h.t.tp:\/\/w.w.w.nhc.gov.cn\/xcs\/zhengcwj\/202301\/32de5b2ff9bf4eaa88e75bdf7223a65a\/files\/460b0e7b19bd42f3bba00c1efb9b6811.pdf."},{"key":"10.1016\/j.clinthera.2025.06.008_bib0017","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0018","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0019","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.7597","article-title":"Comparative effectiveness of digital cognitive behavioral therapy vs medication therapy among patients with insomnia","volume":"6","author":"Lu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0021","unstructured":"Yale Medicine. What to know about EG.5 (Eris)\u2014the latest coronavirus strain. 2023. Accessed September 01, 2024. Available at: https:\/\/www.yalemedicine.org\/news\/covid-eg5-eris-latest-coronavirus-strain."},{"key":"10.1016\/j.clinthera.2025.06.008_bib0022","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1001\/jama.2023.16498","article-title":"What to know about EG.5, the latest SARS-CoV-2 \"variant of interest\"","volume":"330","author":"Abbasi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0023","unstructured":"M. Cascella, M. Rajnik, A. Aleem, et al. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554776\/."},{"key":"10.1016\/j.clinthera.2025.06.008_bib0024","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S2665-9913(21)00322-2","article-title":"Therapeutic implications of ongoing alveolar viral replication in COVID-19","volume":"4","author":"McGonagle","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0025","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3390\/v16060844","article-title":"3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2: validation as a molecular target, proposal of a novel catalytic mechanism, and inhibitors in preclinical and clinical trials","volume":"16","author":"de Freitas Amorim","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0026","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir\/ritonavir (Paxlovid) and comedications","volume":"112","author":"Marzolini","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0027","article-title":"Nirmatrelvir combined with ritonavir for preventing and treating COVID-19","volume":"9","author":"Reis","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0028","unstructured":"U.S. Food & Drug Administration. FDA news release coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19. 2021. Accessed September 01, 2024."},{"key":"10.1016\/j.clinthera.2025.06.008_bib0029","article-title":"Efficacy and safety of nirmatrelvir\/ritonavir (Paxlovid) for COVID-19: a rapid review and meta-analysis","volume":"95","author":"Amani","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0030","article-title":"Association of molnupiravir and nirmatrelvir-ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19","volume":"30","author":"Wai","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"10.1016\/j.clinthera.2025.06.008_bib0031","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jinf.2022.09.027","article-title":"Efficacy and safety of Paxlovid for COVID-19:a meta-analysis","volume":"86","author":"Zheng","year":"2023","journal-title":"J Infect"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0032","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis","volume":"54","author":"Wen","year":"2022","journal-title":"Ann Med"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0033","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0034","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2023.2274511","article-title":"Evaluation of oral small molecule drugs for the treatment of COVID-19 patients: a systematic review and network meta-analysis","volume":"55","author":"Chen","year":"2023","journal-title":"Ann Med"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0035","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJMoa2309003","article-title":"Nirmatrelvir for vaccinated or unvaccinated adult outpatients with Covid-19","volume":"390","author":"Hammond","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0037","doi-asserted-by":"crossref","first-page":"m3379","DOI":"10.1136\/bmj.m3379","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0038","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40262-023-01339-y","article-title":"A comprehensive review of the clinical pharmacokinetics, pharmacodynamics, and drug interactions of nirmatrelvir\/ritonavir","volume":"63","author":"Gerhart","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0039","unstructured":"U.S. Food and Drug Administration. PAXLOVID drug label. 2023. Accessed September 01, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217188s000lbl.pdf."},{"key":"10.1016\/j.clinthera.2025.06.008_bib0040","unstructured":"China Healthcare Security. Simnotrelvir-ritonavir drug label. 2023. Accessed September 01, 2024. Available at: https:\/\/www.nhsa.gov.cn\/attach\/Ypsn2023\/YPSW202300356\/YPSW202300356-W1.pdf."},{"key":"10.1016\/j.clinthera.2025.06.008_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118155","article-title":"Obesity-related drug-metabolizing enzyme expression alterations in the human liver","volume":"187","author":"Kosicka-Noworzy\u0144","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0042","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cmi.2024.09.007","article-title":"Drug-drug interactions of simnotrelvir\/ritonavir: an open-label, fixed-sequence, two-period clinical trial","volume":"31","author":"Ye","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0043","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1111\/bcp.15788","article-title":"Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir\/ritonavir in healthy adults","volume":"89","author":"Cox","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/ph15121455","article-title":"Adverse events associated with nirmatrelvir\/ritonavir: a pharmacovigilance analysis based on FAERS","volume":"15","author":"Li","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0045","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2022034","article-title":"Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea","volume":"44","author":"Jo","year":"2022","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0046","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40801-024-00427-0","article-title":"Economic evaluation of nirmatrelvir\/ritonavir among adults against hospitalization during the Omicron dominated period in Malaysia: a real-world evidence perspective","volume":"11","author":"Low","year":"2024","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.clinthera.2025.06.008_bib0047","unstructured":"Simcere. Fully approved! XianNuoXin\u00ae becomes China\u2019s first routinely approved oral anti-COVID-19 drug. 2024. Accessed September 01, 2024. Available at: https:\/\/www.simcere.com\/news\/detail.aspx?mtt=461."},{"key":"10.1016\/j.clinthera.2025.06.008_bib0048","unstructured":"Chinese Clinical Trial Registry. Study on the therapeutic effect of anti SARS-CoV-2 drugs on COVID-19 patients in Chinese medical and health institutions. 2023. Accessed September 01, 2024. Available at: https:\/\/www.chictr.org.cn\/showproj.html?proj=199288."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T05:01:50Z","timestamp":1763787710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825002140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0149291825002140"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.06.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Simnotrelvir-Ritonavir Compared With Nirmatrelvir-Ritonavir in the Treatment of COVID-19: Real-World Evidence From a Retrospective Cohort Study During the Prevalence of the Omicron EG.5 Variant","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}